The following content is for educational purposes only, is intended for healthcare professionals, and does not supercede local clinical guidelines.
This page will contain downloadable educational resources and links to CaReMe guidelines for the care of patients with cardio-renal-metabolic disorders.
CaReMe UK guidance documents
Guide for non-diabetes specialist physicians and primary care teams for cardiovascular risk optimisation in patients with Type 2 diabetes and atherosclerotic cardiovascular disease. Published 2020. Link
CaReMe UK Publications
- Guidelines in practice: Use a Combined Cardio–Renal–Metabolic Approach to Treat Cardiovascular Disease in Patients With Kidney Disease or Diabetes. https://www.medscape.co.uk/viewarticle/use-combined-cardio-renal-metabolic-approach-treat-2022a10029f1
- Rapid Response to: Rapid response to: SGLT-2 inhibitors or GLP-1 receptor agonists for adults with type 2 diabetes: a clinical practice guideline https://www.bmj.com/content/373/bmj.n1091/rr
- Defining the Role of SGLT2 Inhibitors in Primary Care: Time to Think Differently. https://link.springer.com/article/10.1007/s13300-022-01242-y
- Guidelines in Practice: Manage Diabetes and Comorbidities with a Joined-Up Strategy https://www.medscape.co.uk/viewarticle/manage-diabetes-and-comorbidities-joined-strategy-2022a10017xk
- Guidelines in Practice: Patient Scenarios: CaReMeUK Guidance on the Management of Diabetes and Comorbidities. https://www.medscape.co.uk/viewarticle/patient-scenarios-caremeuk-guidance-management-diabetes-and-2023a10002qu
Other resources
Overcoming hyperkalaemia as a barrier to achieving optimal RAASi therapy and cardiorenal protection in individuals with cardiorenal disease
These resources are intended to be used by healthcare providers in the management of hyperkalaemia in patients with cardiorenal disease receiving renin-angiotensin-aldosterone system inhibitors (RAASi). They were developed by a multi-disciplinary panel of experts, comprising cardiologists, nephrologists, general practitioners, and specialist nurses, organised and funded by AstraZeneca. Healthcare practitioners may use these utilities to assist the development of their own local solutions to issues related to RAAS optimisation.
*Watch this space for details of a forthcoming podcast created by the expert group*
- Practical guide to RAASi* optimisation in individuals with cardiorenal disease
- Practical guide to the definition and management of acute hyperkalaemia in individuals with cardiorenal disease on RAASi* therapy
- Example hospital discharge summary for an individual with cardiorenal disease on RAASi* therapy with hyperkalaemia
- Transfer of care letter for an individual with cardiorenal disease on RAASi* therapy with hyperkalaemia
- Long-term monitoring advice sheet for individuals with cardiorenal disease on RAASi* therapy with hyperkalaemia
- Cardiorenal disease, RAASi* therapy and hyperkalaemia – what does it mean to me?
- Questions to ask your healthcare professional: cardiorenal disease, RAASi* therapy and hyperkalaemia
These utilities were developed by a steering group of cardiorenal experts, organised and funded by AstraZeneca: Andrew H. Frankel1, Kate Bramham2, Barbara Byrne3, Geraldine Chiu4, Ruby Chumber5, Sarah Jane Davies6, Ahmet Fuat7, Laura Gray4, Darren Green8, William Priestman9, Mandie Welch10, Simon G. Williams11, Stephen Wheatcroft12